Your browser doesn't support javascript.
loading
Ventricular assist devices and increased blood product utilization for cardiac transplantation.
Stone, Matthew L; LaPar, Damien J; Benrashid, Ehsan; Scalzo, David C; Ailawadi, Gorav; Kron, Irving L; Bergin, James D; Blank, Randal S; Kern, John A.
Afiliación
  • Stone ML; Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, Virginia.
J Card Surg ; 30(2): 194-200, 2015 Feb.
Article en En | MEDLINE | ID: mdl-25529999
ABSTRACT
BACKGROUND AND AIM OF STUDY The purpose of this study was to examine whether blood product utilization, one-year cell-mediated rejection rates, and mid-term survival significantly differ for ventricular assist device (VAD patients compared to non-VAD (NVAD) patients following cardiac transplantation.

METHODS:

From July 2004 to August 2011, 79 patients underwent cardiac transplantation at a single institution. Following exclusion of patients bridged to transplantation with VADs other than the HeartMate II® LVAD (n = 10), patients were stratified by VAD presence at transplantation VAD patients (n = 35, age 54.0 [48.0-59.0] years) vs. NVAD patients (n = 34, age 52.5 [42.8-59.3] years). The primary outcomes of interest were blood product transfusion requirements, one-year cell-mediated rejection rates, and mid-term survival post-transplantation.

RESULTS:

Preoperative patient characteristics were similar for VAD and NVAD patients. NVAD patients presented with higher median preoperative creatinine levels compared to VAD patients (1.3 [1.1-1.6] vs. 1.1 [0.9-1.4], p = 0.004). VAD patients accrued higher intraoperative transfusion of all blood products (all p ≤ 0.001) compared to NVAD patients. The incidence of clinically significant cell-mediated rejection within the first posttransplant year was higher in VAD compared to NVAD patients (66.7% vs. 33.3%, p = 0.02). During a median follow-up period of 3.2 (2.0, 6.3) years, VAD patients demonstrated an increased postoperative mortality that did not reach statistical significance (20.0% vs. 8.8%, p = 0.20).

CONCLUSIONS:

During the initial era as a bridge to transplantation, the HeartMate II® LVAD significantly increased blood product utilization and one-year cell-mediated rejection rates for cardiac transplantation. Further study is warranted to optimize anticoagulation strategies and to define causal relationships between these factors for the current era of cardiac transplantation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Sustitutos Sanguíneos / Corazón Auxiliar / Trasplante de Corazón / Utilización de Medicamentos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Card Surg Asunto de la revista: CARDIOLOGIA Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Productos Biológicos / Sustitutos Sanguíneos / Corazón Auxiliar / Trasplante de Corazón / Utilización de Medicamentos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Card Surg Asunto de la revista: CARDIOLOGIA Año: 2015 Tipo del documento: Article